Catarina Silva, MSc,  —

InMed Pharmaceuticals has requested approval to start a Phase 1 trial in the Netherlands to test the cannabinoid-based treatment candidate INM-755 for epidermolysis bullosa (EB). Pending approval, the company plans to enroll patients until the end of the year. INM-755 is a topical cream being developed to…

JCR Pharmaceuticals is asking regulators in Japan to extend the use of Temcell HS Injection to epidermolysis bullosa (EB) patients in that country as a wound healing treatment. Temcell HS is a mesenchymal stem cell therapy that approved to treat acute graft versus host disease (aGVHD), a severe complication of allogeneic (donor-derived) bone…